Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Sophie Abadie"'
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology, Vol 17, Iss 1, Pp 27-36 (2023)
Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves t
Externí odkaz:
https://doaj.org/article/ae737b53e2ab4d899bf43ee577ab684b
Autor:
Mylène Annonay, MD, Lisa Gauquelin, MD, Romain Geiss, MD, Mony Ung, MD, Laurence Cristol-Dalstein, MD, Marie-Ange Mouret-Reynier, MD PHD, Anthony Goncalves, MD PHD, Sophie Abadie-Lacourtoisie, MD, Eric Francois, MD, Christophe Perrin, MD, Johan Le Fel, MD, Véronique Lorgis, MD, Véronique Servent, MD, Lionel Uwer, MD, Christelle Jouannaud, MD, Marianne Leheurteur, MD, Florence Joly, MD PHD, Loic Campion, MD, Coralie Courtinard, MPH, Olivier Villacroux, MD, Thierry Petit, MD PHD, Pierre Soubeyran, MD, Catherine Terret, MD, Carine Bellera, PHD, Etienne Brain, MD PHD, Suzette Delaloge, MD MPH
Publikováno v:
Breast, Vol 60, Iss , Pp 138-146 (2021)
Background: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. Methods: Women who initi
Externí odkaz:
https://doaj.org/article/ade3e6c3b78e4adab88c10f438f12991
Autor:
Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer (OC) responsive to first-line platinum-based chemotherapy, including those who
Externí odkaz:
https://doaj.org/article/9ca988f600544d9cb14a5db3e3ba0a1c
Autor:
Florence Joly, Claudia Lefeuvre-Plesse, Claire Garnier-Tixidre, Carole Helissey, Nathalie Menneveau, Alain Zannetti, Sebastien Salas, Nadine Houede, Sophie Abadie-Lacourtoisie, Laetitia Stefani, Soazig Nenan, Isabelle Rieger, Isabelle Durand-Zaleski, Jean-Marc Descotes, Amélie Anota
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Currently, oral targeted therapies are known to be effective and are frequently used to treat metastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue may impact the pati
Externí odkaz:
https://doaj.org/article/8454578e57ce4e9ea28dc9f15cf6946e
Autor:
Paule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, Carole Gourmelon, Sophie Abadie Lacourtoisie, Dominique Berton Rigaud, Patrick Soulié, Jean Sebastien Frenel, Mario Campone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Endocrine therapy is the mainstay of treatment of estrogen-receptor-positive (ER+) breast cancer with an overall survival benefit. However, some adaptive mechanisms in the tumor emerge leading to the development of a resistance to this therapy. A bet
Externí odkaz:
https://doaj.org/article/ca4c0958e557434eae385369c0c3ecc5
Autor:
Loriot, Yohann, Texier, Matthieu, Culine, Stéphane, Fléchon, Aude, Thiery-Vuillemin, Antoine, Gravis, Gwenaëlle, Geoffrois, Lionel, Chevreau, Christine, Gross-Goupil, Marine, Barthelemy, Philippe, Bompas, Emmanuelle, Mahammedi, Hakim, Laguerre, Brigitte, Lacourtoisie, Sophie Abadie, Helissey, Carole, Ladoire, Sylvain, Abraham, Christine, Massard, Christophe, Grimaldi, Serena, Fizazi, Karim
Publikováno v:
In European Urology August 2022 82(2):172-179
Autor:
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, Nicolas Delanoy, Florence Joly, Alain Lortholary, Benoît You, Patrick Bouchaert, Emmanuelle Malaurie, Sebastien Gouy, Marie-Christine Kaminsky, Jérôme Meunier, Jérôme Alexandre, Dominique Berton, Nadine Dohollou, Coraline Dubot, Anne Floquet, Laure Favier, Laurence Venat-Bouvet, Michel Fabbro, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Christophe Desauw, Francesco Del Piano, Marianne Leheurteur, Nathalie Bonichon-Lamichhane, Mansour Rastkhah, Philippe Follana, Justine Gantzer, Isabelle Ray-Coquard, Eric Pujade-Lauraine
Publikováno v:
Gynecologic Oncology. 170:186-194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14cec58707cd7c4b5aefc675bf3bf5db
https://doi.org/10.1016/j.ygyno.2023.01.008
https://doi.org/10.1016/j.ygyno.2023.01.008
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology. 17:27-36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::929dd2cc532a0879cba0fe2fca6520b0
https://doi.org/10.1002/1878-0261.13340
https://doi.org/10.1002/1878-0261.13340
Autor:
Yohann Loriot, Matthieu Texier, Stéphane Culine, Aude Fléchon, Antoine Thiery-Vuillemin, Gwenaëlle Gravis, Lionel Geoffrois, Christine Chevreau, Marine Gross-Goupil, Philippe Barthelemy, Emmanuelle Bompas, Hakim Mahammedi, Brigitte Laguerre, Sophie Abadie Lacourtoisie, Carole Helissey, Sylvain Ladoire, Christine Abraham, Christophe Massard, Serena Grimaldi, Karim Fizazi
Publikováno v:
European Urology. 82:172-179
In metastatic seminoma, a strategy is needed for selecting patients for less intensive chemotherapy, to limit toxicities.To assess whether men with good-prognosis metastatic seminoma could be treated with two cycles of etoposide-cisplatin (EP) follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66071940c3c896a355f7086132d5342b
https://doi.org/10.1016/j.eururo.2022.04.031
https://doi.org/10.1016/j.eururo.2022.04.031
Autor:
Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, Benoit You
Purpose:In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4796f6127c2ed9abe0f35b718eb64beb
https://doi.org/10.1158/1078-0432.c.6529656
https://doi.org/10.1158/1078-0432.c.6529656
